Human Genome Sciences (HGSI) Said BENLYSTA Met Primary Endpoint
Down)
Human Genome Sciences, Inc. (NASDAQ: HGSI) and GlaxoSmithKline PLC (NYSE: GSK) announced that BENLYSTA met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE).
In the placebo-controlled BLISS-52 study, the results showed that BENLYSTA plus standard of care achieved a clinically and statistically significant improvement in patient response rate at Week 52, compared with standard of care alone. Study results also showed that belimumab was generally well tolerated, with adverse event rates comparable between belimumab and placebo treatment groups.
Shares of HGSI are surging in pre-open trading.
In the placebo-controlled BLISS-52 study, the results showed that BENLYSTA plus standard of care achieved a clinically and statistically significant improvement in patient response rate at Week 52, compared with standard of care alone. Study results also showed that belimumab was generally well tolerated, with adverse event rates comparable between belimumab and placebo treatment groups.
Shares of HGSI are surging in pre-open trading.
You May Also Be Interested In
- UPDATE: Angelo, Gordon to Acquire Benihana (BNHN) for $16.30/Share in Cash
- Corinthian Colleges (COCO) Bounces Off Intraday Lows into Close
- UPDATE: SAP's (SAP) America Unit to Buy Ariba (ARBA) for $45/Share
Create E-mail Alert Related Categories
FDA, Hot List, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
